Correlation of immune responses with survival in a randomized phase II study investigating multipeptide vaccination with IMA901 plus or minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC).

H Singh,R Mendrzyk,C Reinhardt,N Hilf,D Maurer,A Kirner,T Weinschenk,S Walter,A Stenzl,J Frisch

doi:10.1200/jco.2010.28.15_suppl.2587

Correlation of immune responses with survival in a randomized phase II study investigating multipeptide vaccination with IMA901 plus or minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC).

H Singh, R Mendrzyk + Show 8 more

https://doi.org/10.1200/jco.2010.28.15_suppl.2587

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2010
Citations: 4

#Correlation Of Immune Responses #Advanced Renal Cell Carcinoma #Renal Cell Carcinoma #HLA Class #Therapeutic Vaccine #Class II-binding Peptides #II-binding Peptides #Therapeutic Cancer Vaccine #Multipeptide Vaccination #Tumor-associated Peptides

Abstract
Full-Text
Similar Papers

Abstract

Listen

2587 Background: IMA901 is a therapeutic cancer vaccine based on the selection of naturally presented tumor-associated peptides (9 HLA class I- and 1 HLA class II-binding peptides). A previous phas...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Correlation of immune responses with survival in a randomized phase II study investigating multipeptide vaccination with IMA901 plus or minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC).